Rapid Transient and Stable Protein Production with Consistent Quality to Accelerate Biotherapeutic Development.

Weili Wang, Rama Shivakumar, Pachai Natarajan, James Brady, Krista Steger and Madhusudan Peshwa. MaxCyte, Gaithersburg, MD, USA.

Abstract

Rapid recombinant protein production is one of the key elements for drug development success. However, to consistently produce good quality biotherapeutic molecules transiently it is still quite challenging due to consistency and scalability issues. Therefore, high levels of process consistency and scalability are important not only for GMP stage manufacturing, but they are also critical for early stage R&D studies since good predictability of any scale production can shorten timelines and minimize costs. The aim of this study is to show how Flow Electroporation™ Technology can transiently produce therapeutic materials from milligram to gram scales quickly to support early to mid-stage drug development. We will present our data to demonstrate a) the robustness of the platform for protein expression in different cell lines (Antibody titers of 2 pg/1E6 cells were obtained by transient gene expression in CHO-S cells), b) the great scalability and consistency of the technology from 0.5 x 106 to 2 x 1011 of the transfected cells and c) the comparable protein quality between transient expression lots and also comparable quality of protein produced by a stable cell line. So the high transient productivity, product quality and scalability in CHO cells by using Flow Electroporation™ Technology can accelerate the drug development process and reduce the risk of drug evaluation and selection. And potentially transient expressed recombinant proteins could be used for clinic study in future.

Universal, High-Level Transfection Efficiency and Cell Viability

MaxCyte Transient Transfection Platform

Rapid Production of Recombinant Proteins for Use as Vaccines

High Cell Viability Leads to Strong HIV gp145 Expression

Figure 1. High Efficiency Transfection of Cell Types Commonly Used for Protein and Vaccine Production. Various cells were transfected with 2 pg/1E6 cells of pSP DNA using the appropriate MaxCyte STX protocol. Cells were examined for GFP expression using fluorescence microscopy 24 hrs post electroporation.

Figure 2. Post Electroporation Culture Process Optimization Produces CHO-S Antibody Titers >2.7 g/L. CHO-S cells were transfected with an antibody expression plasmid (1 pg DNA/1E6 cells) via small scale electroporation on the MaxCyte STX. Cells were plated approximately 4E6 cells/mL post electroporation. Transfected cells were cultured in media with different additive and culture conditions. Titers were verified by both ELISA and Protein A capture assays. The optimized process produced antibody titers of 2.74 g/L at day 17 post EP as a fed batch.

Figure 3. Cell Viability and Protein Titer Data Following Transfection of CHO Cells with an HIV Envelope Protein Expression Plasmid. CHO cells were transfected with a gp145 expression plasmid via small scale EP (867 cells) and large scale EP (967 cells). Transfected cells were inoculated into shake flasks at the same density and cultured for 10 days. Cells from the small scale and large scale EPs yielded consistent titers and exhibited high viabilities. Viabilities and titers from the electroporated cells were much higher than corresponding values for a customer’s optimized PEI process.

Figure 4. Rapid Production of Recombinant Proteins for Use as Vaccines. High Cell Viability Leads to Strong HIV gp145 Expression

The high transfection efficiency and cell viability rates of MaxCyte’s electroporation are shown here.

Figure 5. MaxCyte STX to VLX Instrument Scale-up Exhibits Consistent Protein Titers, Cell Viabilities, and Growth Kinetics. Duplicate sets of 2E10 CHO-S cells were transfected with an hIgG1 expression plasmid (1 pg/1E6 cells) via flow electroporation with the MaxCyte STX or the VLX. Transfected cells were seeded into 1 L cultures at a starting density of 4E6 cells/mL, and fed batch cultures were maintained for 15 days. Secreted protein titers were monitored by ELISA; cells counts and viabilities were measured via trypan blue staining. Error bars denote standard deviations from three replication shake flasks.

Figure 6. Rapid, High-Yield Stable Cell Generation. A stable pool of CHO cells expressing an hIgG1 was generated within two weeks of electroporation. 473 clones were screened following limited dilution cloning. The top clone was selected for production within 6 weeks post electroporation. Production was carried out in shake flasks as a fed batch. At day 17, productively reached 5.5 g/L. Results were verified by both ELISA and Protein A capture assays.

Figure 7. hIgG1 Quality & Glycosylation Similar IgGs Produced via MaxCyte Transient Transfection & Stable Cell Lines Generated Using MaxCyte Transfection

Rapid, High-Yield Stable Cell Generation Stable Cell Lines Generated in 6 Weeks

MaxCyte Transient Transfection Platform

MaxCyte STX®
325 Cells in Seconds
Up to 2E10 Cells in ~30 min

MaxCyte VLX®
Up to 2E11 Cells in ~30 min

Figure 8. MaxCyte STX and MaxCyte VLX Transient Transfection Systems use fully scalable flow electroporation for rapid, highly efficient transfection.

The MaxCyte STX® and MaxCyte VLX® Transient Transfection Systems use fully scalable flow electroporation for rapid, highly efficient transfection.

- High efficiency & high cell viability
- Broad cell compatibility
- True scalability requiring no re-optimization
- Closed, computer-controlled instruments
- cGMP-compliant & CE-marked
- Master file with US FDA & Health Canada

Figure 9. MaxCyte Transient Transfection Platform

MaxCyte STX®
325 Cells in Seconds
Up to 2E10 Cells in ~30 min

MaxCyte VLX®
Up to 2E11 Cells in ~30 min

Summary

- The high transfection efficiency and cell viability rates of MaxCyte’s electroporation-based, delivery platform enable rapid production of therapeutics molecules via transient or stable expression leading to accelerated candidate development.
- Flow Electroporation™ Technology is universal in nature and can produce a variety of high quality, functional protein types including full IgGs, bispecics, bispecifics and Fc fusion proteins (data not shown).
- Transient transfection of CHO cells produces the gram-scale quantities of antibodies needed for early and mid-stage development reducing early reliance on stable cell generation.
- Antibodies (IgG) transiently transduced via Flow Electroporation™ Technology exhibit glycosylation and protein characteristics similar to stably produced protein, supporting the use of transiently produced proteins in early-stage discovery efforts.
- High CHO cell viability post electroporation enables rapid generation of stable pools and development of stable clones in 6 weeks with yields >5.7 g/L. High cell viability enabled stronger antibody selection which enriches for high yield clones. Fewer than 500 clones needed to be screened to identify a high-yield stable cell line.
- The MaxCyte Scalable Transfection Systems offer a highly consistent delivery platform that provides the speed, scalability and cGMP compliance for use in biomanufacturing of therapeutics and vaccines.